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ABSTRACT 
The clinical course of relapse-onset multiple sclerosis is highly variable. Demographic factors, 
clinical features and global brain T2 lesion load have limited value in counselling individual 
patients. We investigated early MRI predictors of key long-term outcomes including secondary 
progressive multiple sclerosis, physical disability and cognitive performance, 15 years after a 
clinically isolated syndrome (CIS). A cohort of CIS patients (n=178) was prospectively 
recruited within 3 months of clinical disease onset and studied with MRI scans of the brain and 
spinal cord at study entry (baseline) and after 1- and 3-years. MRI measures at each time point 
included: supratentorial, infratentorial, spinal cord and gadolinium-enhancing lesion number, 
brain and spinal cord volumetric measures. The patients were followed-up clinically after ~15 
years to determine disease course, and disability was assessed using the Expanded Disability 
Status Scale (EDSS), Paced Auditory Serial Addition Test (PASAT) and Symbol Digit 
Modalities Test (SDMT). Multivariable logistic regression and multivariable linear regression 
models identified independent MRI predictors of secondary progressive multiple sclerosis and 
EDSS, PASAT and SDMT respectively. After 15 years, 166 (93%) patients were assessed 
clinically: 119 (72%) had multiple sclerosis (94 [57%] relapsing-remitting, 25 [15%] secondary 
progressive), 45 (27%) remained CIS and 2 (1%) developed other disorders. Physical disability 
was overall low in the multiple sclerosis patients (median EDSS 2, range 0 – 10); 71% were 
untreated. Baseline gadolinium-enhancing (odds ratio [OR] 3.16, p<0.01) and spinal cord 
lesions (OR 4.71, p<0.01) were independently associated with secondary progressive multiple 
sclerosis at 15 years. When considering 1- and 3-year MRI variables, baseline gadolinium-
enhancing lesions remained significant and new spinal cord lesions over time were associated 
with secondary progressive multiple sclerosis. Baseline gadolinium-enhancing (β=1.32, 
p<0.01) and spinal cord lesions (β=1.53, p<0.01) showed a consistent association with EDSS 
at 15 years. Baseline gadolinium-enhancing lesions was also associated with performance on 
the PASAT (β= -0.79, p<0.01) and SDMT (β= -0.70, p=0.02) at 15 years. Our findings suggest 
that early focal inflammatory disease activity and spinal cord lesions are predictors of very 
long-term disease outcomes in relapse-onset multiple sclerosis. Established MRI measures, 
available in routine clinical practice, may be useful in counselling patients with early multiple 








The course of relapse-onset multiple sclerosis is highly variable with marked differences in the 
rate of disease progression, accrual of physical disability and cognitive impairment. 
Demographic and clinical variables have limited value of predicting the course of multiple 
sclerosis in individual patients and there is a need for robust prognostic markers in people with 
early multiple sclerosis to: (1) inform patients about how their condition might progress in the 
future; (2) to help select disease-modifying therapies and personalise treatment plans; and (3) 
to identify patients at high-risk for disease progression in order to target future neuroprotective 
treatments.  
 
Magnetic resonance imaging (MRI) is an established prognostic marker in patients with 
clinically isolated syndromes (CIS) suggestive of multiple sclerosis. Asymptomatic T2-
hyperintense brain lesions are helpful in identifying patients at high-risk of a second clinical 
attack (Fisniku et al., 2008; Optic Neuritis Study Group, 2008; Tintore et al., 2015), but the 
relationship between brain T2 lesion load and long-term disability is less robust. Previous 
studies with long-term follow-up (>10 years) have found only a modest relationship between 
global brain T2 lesion load at CIS onset and later physical disability (Fisniku et al., 2008; Optic 
Neuritis Study Group, 2008). Change in global brain T2 lesion load, particularly in the first 
few years after disease onset, may have a stronger relationship with long-term physical 
disability, albeit still limited (Fisniku et al., 2008).  Lesion location and activity may be better 
predictors of future physical disability, at least in the short to medium term. Asymptomatic 
infratentorial (Minneboo et al., 2004; Swanton et al., 2009; Tintore et al., 2010), spinal cord 
(Swanton et al., 2009; Brownlee et al., 2017; Arrambide et al., 2018) and gadolinium-
enhancing lesions (Swanton et al., 2009; Di Filippo et al., 2010) are associated with the 
development of physical disability (measured using the Expanded Disability Status Scale 
[EDSS]) over the first 5 – 7 years after a CIS.  
 
In the longer term, the onset of secondary progression is the major determinant of physical 
disability in relapse-onset multiple sclerosis. Natural history studies suggest that half of patients 
will develop secondary progressive multiple sclerosis in the first 15 years after disease onset 
(Scalfari et al., 2014), although more recent observational cohorts suggest this risk may be 
lower than previously thought (Kerbrat et al., 2015; Cree et al., 2016). Identifying patients with 
a shorter latency to onset of secondary progression is a key priority in order to select appropriate 
treatments strategies Whether lesional MRI abnormalities associated with short-term changes 
in physical disability (Swanton et al., 2009; Tintore et al., 2010; Brownlee et al., 2017; 
Arrambide et al., 2018) are also important in the development of secondary progressive 
multiple sclerosis and long-term disability is unclear.  
 
Cognitive impairment is also an important source of disability in people with multiple sclerosis, 
impacting on physical functioning, quality of life and employment. Cognitive impairment can 
develop in the absence of significant physical disability and is not adequately captured by 
commonly used multiple sclerosis disability metrics, including the EDSS. Advanced MRI 
measures including whole brain and grey matter tissue damage (detected using magnetization 
transfer imaging) and short-term changes in brain volume have been associated with long-term 
cognitive impairment in established multiple sclerosis (Deloire et al., 2011; Filippi et al., 
2013). However, the relationship between conventional MRI measures available in routine 
clinical practice, such as T2 lesion load, location and activity, and long-term cognitive 
performance is unresolved.  
 
We aimed to identify early MRI predictors of long-term outcomes in relapse-onset multiple 
sclerosis, including (i) secondary progressive disease course; (ii) physical disability; and (iii) 
cognitive performance. We studied a cohort of patients with clinically isolated syndromes 
suggestive of multiple sclerosis who had MRI scans around the time of presentation and follow-
up MRI scans after 1 and 3 years. We investigated the prognostic value of established MRI 
measures available clinically (including T2 lesion number, lesion location and gadolinium-
enhancing lesions), plus early changes in brain and spinal cord volume, in the earliest stages of 
relapse-onset multiple sclerosis are associated with outcomes after 15 years. 
 
MATERIALS AND METHODS 
Patients 
Between 1995 and 2004, patients seen at the National Hospital for Neurology and 
Neurosurgery and Moorfields Eye Hospital, London, United Kingdom with CIS suggestive of 
multiple sclerosis were invited to take part in a longitudinal clinical and imaging study. The 
inclusion criteria for the study: (1) age 16-50 years; (2) a “typical” syndrome suggestive of 
multiple sclerosis e.g. unilateral optic neuritis, partial myelitis, brainstem/cerebellar syndrome; 
and (3) no previous history of neurological symptoms. All of the patients were assessed 
clinically and with MRI within 3 months of presentation and invited to return for scheduled 
clinical and MRI follow-up after approximately 1, 3 and 5 years (Swanton et al., 2009; 
Brownlee et al., 2017). Between 2014 and 2016 (~15 years after disease onset) all patients were 
then invited to attend a long-term, clinical follow-up to ascertain clinical status and disability.  
 
All patients provided written informed consent at the time of study entry and consent for 
continued participation in the study was obtained at each follow-up. The study was approved 
by the institutional research ethics committee and conducted in accordance with the 
Declaration of Helsinki. 
 
Clinical assessments 
Multiple sclerosis was diagnosed at 15 years using the McDonald 2010 criteria (Polman et al., 
2011) and disease course was classified as CIS, relapsing-remitting multiple sclerosis or 
secondary progressive multiple sclerosis using the Lublin and Reingold 1996 disease course 
definitions (Lublin et al., 1996). At the last clinical visit, about 15 years after disease onset, 
physical disability was assessed using the Expanded Disability Status Scale (EDSS), the timed 
25-foot walk test (TWT) and the 9-hole peg test (9-HPT) by one examiner (WJB). Cognition 
was assessed using the Paced Auditory Serial Addition Test (PASAT) (Cutter et al., 1999) and 
Symbol Digit Modalities Test (SDMT) (Smith, 1982) by the same clinician (WJB). The 
PASAT and SDMT scorers were concerted to z-scores using published age-matched norms, 
and patients with a z-score ≤ -1.5 were considered impaired. Premorbid cognitive performance 
was estimated using the National Adult Reading Test (NART) (Nelson, 1982). Self-reported 
fatigue was measured using the Fatigue Severity Scale (FSS) (Krupp et al., 1989), with patients 
with scores of ≥5 classified as “fatigued” (Tellez et al., 2006). 
 
Physical disability was assessed using the telephone EDSS in people who were unable to attend 
in person for follow-up (Lechner-Scott et al., 2003). Disease course and disability was 
corroborated wherever possible using hospital records in patients who were assessed by 
telephone interview. 
 
MRI protocol and image-analysis 
The patients underwent MRI scans of the brain and whole spinal cord within 3 months of CIS 
onset (“baseline”) and then after approximately 1 year and 3 years (Figure 1). Details of the 
MRI acquisition protocol are shown in Supplementary Table 1. All of the MRI scans were done 
on the same 1.5T Signa scanner (General Electric, Wisconsin, USA).  
 
All MRI scans were reviewed by an experienced neuroradiologist who was blinded to the 
patient’s clinical status. The number of T2-hyperintense supratentorial, infratentorial and spinal 
cord lesions at baseline, and the number of new lesions after 1 year and 3 years, was recorded 
from proton density (PD)/T2-weighted scans of the brain and whole spinal cord. The number 
of gadolinium-enhancing lesions at baseline, 1 and 3 years was identified from post-contrast 
2D T1-weighted scans. For brain volumetric measurements we used post-contrast 2D T1-
weighted scans. T1-hypointense lesions were identified on the 2D T1-weighted scans and 
outlined using a semi-automated edge finding tool (JIM6, Xinapse systems, Aldwincle,UK). 
Lesion masks used to fill T1-hypointense lesions (Prados et al., 2016). The normalised brain 
volume (NBV) at baseline was calculated using SIENAX and the percentage brain volume 
change (PBVC) at 1- and 3-years (compared to baseline) was calculated using SIENA. The 
SIENAX and SIENA analyses used brain extraction tool (BET) for the skull only and the brain 
tissue mask was computed using Similarity and Truth Estimation for Propagated 
Segmentations (STEPS), to avoid bias due to cerebrospinal fluid (Cardoso et al., 2013; Cawley 
et al., 2018). The mean upper cervical cord cross-sectional area (UCCA) at the level of C2/C3 
from reformatted sagittally-acquired images using an active surface model, as previously 
described (Horsfield et al., 2010; Brownlee et al., 2017). The UCCA at baseline plus the 
absolute change and percentage change in UCCA after 1-year and 3-years were calculated.  
 
Statistical analysis 
Descriptive statistics are presented as median (interquartile range) unless otherwise stated. 
Patients were grouped by clinical status at 15 years (CIS, relapsing-remitting multiple sclerosis, 
secondary progressive multiple sclerosis). The Mann-Whitney U test was used to investigate 
differences in MRI measures at baseline and changes in MRI measures over time in different 
patient groups.  
 
Multivariable logistic regression models were used to identify independent predictors of 
conversion to secondary progressive multiple sclerosis at 15 years. Three separate models were 
constructed using MRI data available at each of the three time points, and also using the 
following potential confounders: baseline EDSS, age at onset, gender, type of CIS presentation, 
the exact interval in years between onset and the 15-year assessment (i.e. disease duration). 
Use of disease-modifying treatments was not included, since the reverse causation involved in 
selecting patients for treatment (resulting in use disease-modifying treatments predicting 
greater odds of worse disease course) distorts the association between earlier variables and 
outcome. The following MRI data were included in each model:    
 
(i) Baseline model – MRI predictor variables were supratentorial, infratentorial, spinal 
cord and gadolinium-enhancing lesion number, using either binary (0/1+) or 
categorical (0/1/2+) alternatives); and NBV and UCCA as continuous variables.   
 
(ii) 1-year model – baseline MRI predictors (again using binary or categorical 
alternatives) plus the change in supratentorial, infratentorial and spinal cord lesion 
number at 1 year, the number of gadolinium-enhancing lesions at 1 year; and as 
continuous variables the PBVC from baseline to 1 year and the change in UCCA 
from baseline to 1 year. 
 
(iii) 3-year model – baseline and 1-year MRI predictors (again using binary or 
categorical alternatives) plus the change in supratentorial, infratentorial and spinal 
cord lesion number at 3 years, the number of gadolinium-enhancing lesions at 3 
years; and as continuous variables the PBVC from baseline to 3 year and the change 
in UCCA from baseline to 3 year. 
 
 
For these logistic regression models a manual forward step-wise process was used for the MRI 
predictors. The non-MRI baseline potential confounders were added singly to the best MRI 
models, and retained only if they materially affected either the MRI coefficients or their p-
values, or were themselves significant. These potential confounders had a negligible impact on 
the MRI contributions, and were themselves non-significant, so were excluded from reported 
models. The binary form of MRI predictors was used unless the categorical alternative 
significantly improved model fit (assessed by log likelihood ratio comparison of nested 
models). Model predicted probabilities are reported for the various combinations of MRI 
predictor values.  Overall model fit is reported using the model C-statistic (0.5, no predictive 
power, to 1, perfect prediction) and the model accuracy (using a 0.5 probability cut-off). 
 
The same process was used to build multiple linear regression models for 15-year EDSS, the 
MSFC components, and SDMT. Baseline EDSS, age at onset, gender, type of CIS presentation 
and disease duration were investigated as possible confounders in the models, along with years 
of education and NART pre-morbid IQ (NART) for the PASAT and SDMT. Regression 
residuals showed no heteroscedasticity or important deviations from normality, but for EDSS 
as a precaution model inferences were checked using a non-parametric bias-corrected and 
accelerated bootstrap with 2000 replications; these bootstrap confidence intervals did not 
materially differ from the Normal-based estimates, so the latter are reported. Note, however, 
that for EDSS although the regression p-values, confidence intervals and R-squares are valid 
after the residual checks above, regression coefficients must be interpreted with caution: 
although they are meaningful relatively as comparisons of the strength of predictor 
associations, they are of limited value in absolute terms since the EDSS scale does not have a 
uniform linear interpretation.      
 
Statistical analysis was performed in Stata 14.1.  Statistical significance is reported as p<0.05. 
 
Data availability 




Out of 178 patients who were enrolled into the study at baseline, 166 (93%) were followed up 
after a mean of 15.1 years (range 11.2 – 19.7 years). Two patients were diagnosed with 
neuromyelitis optica spectrum disorder during follow-up (one each with aquaporin 4-IgG and 
myelin oligodendrocyte glycoprotein-IgG antibodies) and were excluded, leaving 164 patients. 
Disease course and physical disability at 15 years was assessed by telephone interview in 47 
(29%) patients. The reasons for telephone interview were patient choice (n=34), living overseas 
(n=8), severe disability (n=3) and pregnancy (n=2). The baseline characteristics of the study 
cohort who were followed up after 15 years are shown in Table 1. 
Disease course and disability after 15 years 
During follow-up 119 (73%) patients developed multiple sclerosis and 45 (27%) patients 
remained CIS (i.e. a single clinical attach without MRI evidence of dissemination in space and 
time). At the time of CIS, 48 (29%) patients had MRI evidence of dissemination in space and 
time, so retrospectively would be classified as having multiple sclerosis. The proportion of 
patients who developed multiple sclerosis was similar in patients who presented with optic 
neuritis (74%), brainstem/cerebellar (65%) and spinal cord (64%) syndromes. Disease course 
was classified as relapsing-remitting multiple sclerosis in 94 (57% of the total cohort) patients 
and secondary progressive multiple sclerosis in 25 (15%) patients after 15 years. Thirty-four 
(21%) patients (all with multiple sclerosis) were receiving disease-modifying therapies at the 
time of follow-up, or had been exposed to one or more treatments in the past, including 
interferon-β (n=22), glatiramer acetate (n=11), natalizumab (n=5), fingolimod (n=4), dimethyl 
fumarate (n=1), teriflunomide (n=1) and alemtuzumab (n=1). The median time to starting 
disease-modifying therapy was 50 months (range 3 – 182 months) after CIS. Only 7 (4%) 
patients had been exposed to disease-modifying therapies for >6 months at the time of the 1 
and/or 3 year follow-up MRI scans. 
The median EDSS at follow-up was 0 (range 0 – 1) in patients who remained CIS and 2.0 
(range 0 – 10) in patients with multiple sclerosis. A wide range of physical disability 
encompassing all levels of the EDSS was seen in the patients with multiple sclerosis at follow-
up (Figure 2). Three patients had died from complications of severe multiple sclerosis and were 
assigned EDSS 10. The median EDSS at 15 years was similar in patients with different CIS 
presentations: optic neuritis 1.5 (range 0 – 10), brainstem syndrome 1.5 (range 0 – 10) and 
spinal cord syndrome 2.5 (range 0 – 8.5).  
 
Cognition and self-reported fatigue were assessed in 104 (63%) patients at 15 years. Twenty-
one (20%) patients had impaired performance on the PASAT and 27 (26%) patients on the 
SDMT, all of whom had multiple sclerosis. FSS scores in the fatigued range were reported in 
31 (30%) patients, 29 of whom had multiple sclerosis.   
 
Among the 12 (7%) patients who were lost to follow-up at 15 years, 75% were men. The other 
baseline demographic and clinical characteristics were similar. The mean follow-up for these 
patients was 3.8 years (range 0.6 – 8.7 years) and 9 (75%) were known to have developed 
multiple sclerosis with a median EDSS of 1 (range 0 – 2.5) at last follow-up. 
 
Baseline and changes over the first 3 years predict secondary progressive course after 
15 years 
The baseline MRI scan was done a median of 44 days (range 4 – 90 days) after CIS onset. The 
baseline brain MRI showed one or more asymptomatic T2-hyperintense lesion(s) in 125 (76%) 
patients. Multiple sclerosis developed in 111 of 125 (89%) patients with an abnormal brain 
MRI at baseline and 8 of 39 (21%) with a normal brain MRI. The baseline spinal cord MRI 
showed one or more asymptomatic T2-hyperintense lesion(s) in 58 (35%) patients. Multiple 
sclerosis developed in all 58 (100%) patients with an abnormal spinal cord MRI at baseline and 
in 62 of 106 (58%) patients with a normal spinal cord MRI. The baseline MRI showed one or 
more asymptomatic gadolinium-enhancing lesion(s) in 52 (32%) patients (49 brain MRI only, 
3 spinal cord MRI only, 3 brain and spinal cord MRI). Multiple sclerosis developed in 51 (98%) 
patients with gadolinium-enhancing lesions. One patient with a single contrast-enhancing 
symptomatic brainstem lesion remained CIS. 
 
At baseline, the patients who developed secondary progressive multiple sclerosis at 15 years 
had a higher median number of spinal cord lesions (1 vs 0, p=0.022) compared with patients 
who remained relapsing-remitting multiple sclerosis. The other baseline MRI findings were 
similar (Table 1).  
 
Follow-up MRI scans of the brain and spinal cord were obtained after 1 (n=135) and 3 (n=121) 
years (Supplementary Table 2). Over the first year after CIS, the patients who developed 
secondary progressive multiple sclerosis showed a higher median number of new supratentorial 
(7 vs 5, p=0.045), infratentorial (1 vs 0, p<0.001) and spinal cord (1 vs 0, p=0.001) lesions 
compared with those with relapsing-remitting multiple sclerosis at 15 years (Supplementary 
Table 2). At 3 years, the patients who developed secondary progressive multiple sclerosis at 15 
years also showed a higher median number of new infratentorial (2.5 vs 0, p=0.015) and spinal 
cord lesions (2.5 vs 0, p<0.001), and a higher number of gadolinium-enhancing lesions (1 vs 
0, p=0.030) compared to the group with relapsing-remitting multiple sclerosis. A similar rate 
of brain and spinal cord atrophy was observed in both groups over the first 3 years after disease 
onset. 
 
Early MRI predictors of long-term secondary progressive multiple sclerosis course 
using regression models 
Three multivariable logistic regression models, for potential predictors available at the three 
time points, were constructed to investigate the relationship between the development of 
secondary progressive multiple sclerosis at follow-up and early MRI abnormalities (Table 2). 
In the baseline MRI model gadolinium-enhancing lesions (≥2 lesions) and spinal cord lesions 
(≥1) were independently associated with a higher odds of conversion to secondary progressive 
at 15 years (C-statistic 0.76). In patients with no gadolinium-enhancing lesions and no spinal 
cord lesions at the time of CIS the estimated risk of secondary progressive multiple sclerosis 
at 15 years was 5.3% (95% CI 1.1, 9.5%), compared with 45.5% (95% CI 24.7, 66.4%) in those 
with at least one spinal cord lesion and two or more gadolinium-enhancing lesions.  
 
In the model incorporating baseline and follow-up MRI data over 1 year, baseline gadolinium-
enhancing lesions remained significant, and ≥1 new spinal cord and infratentorial lesions at 1 
year were independently associated with a higher odds of secondary progressive multiple 
sclerosis at 15 years (C-statistic 0.86). In patients with no gadolinium-enhancing lesions at 
baseline and no new spinal or infratentorial lesions after 1 year the estimated risk of secondary 
progressive multiple sclerosis after 15 years was 3.0% (95%CI 0, 6.2%), compared with 85.2% 
(95% CI 67.7, 100%) in people with two or more gadolinium-enhancing lesions at baseline and 
new spinal and infratentorial lesions at 1 year. Finally, in the model incorporating all MRI data 
from baseline to 3 years, ≥1 new spinal cord lesions, and with borderline significance ≥1 new 
infratentorial lesions, were independently associated with a higher odds of secondary 
progressive multiple sclerosis at 15 years (C-statistic 0.89). In patients with no new spinal or 
infratentorial lesions over the first 3 years after CIS the estimated risk of secondary progressive 
multiple sclerosis after 15 years was 0.9% (95%CI 0, 2.7%), compared with 53.1% (31.7, 
74.6%) in patients with  ≥1 new spinal and  ≥1 new infratentorial lesions at 3 years.   
 
Age, sex, CIS type, baseline EDSS and duration of follow-up had no material effect on any of 
the models, were not themselves significant, so were not retained. 
 
Early MRI predictors of long-term physical disability 
Multivariable linear regression models were used to examine the association of EDSS at 15 
years and early MRI abnormalities at baseline, 1-year and 3-years (Table 3). In the model 
investigating baseline MRI predictors of long-term EDSS, ≥1 baseline supatentorial, 
gadolinium-enhancing and spinal cord lesions were independently associated with higher 
EDSS scores at 15 years (R2=0.31). In the 1-year model, ≥1 baseline gadolinium-enhancing 
lesions and spinal cord lesions remained significant, and ≥1 new supatentorial, infratentorial 
and spinal cord lesions at 1-year were also associated with EDSS at 15 years (R2=0.48). Finally, 
in the model considering all time points over the first 3 years after CIS, ≥1 baseline gadolinium-
enhancing and spinal cord lesions remained significant, and ≥1 new spinal cord lesions and the 
PBVC at 3 years were also associated with higher EDSS (R2=0.58).  
  
TWT and 9HPT scores were available in a subgroup of patients at 15 years (n=112). One or 
more baseline gadolinium-enhancing and spinal cord lesions were independently associated 
with slower walking speed, and ≥1 baseline gadolinium-enhancing lesions with worse 9HPT 
performance at 15 years.  
 
Age, sex, CIS topography, baseline EDSS and duration of follow-up did not have any influence 
on the regression coefficients and were not retained in the final models examining physical 
disability. 
 
Early MRI predictors of long-term cognitive performance 
Cognitive testing was done in a subgroup of patients at 15 years (n=104). Multivariable linear 
regression models were used to examine the association of early MRI measures with long-term 
cognitive performance on the PASAT and SDMT (Table 4). One or more baseline gadolinium 
enhancing lesions were associated with reduced performance on the PASAT at 15 years. When 
1-year MRI variables were included in the model ≥1 baseline gadolinium enhancing lesions 
remained significant and ≥ 1 new supratentorial lesions at 1 year were also associated with 
reduced performance on the PASAT at 15 years. The findings were similar for the SDMT 
(Table 4). The NART score, an estimate of premorbid intelligence, was significantly associated 
with PASAT (higher NART score associated with better PASAT performance) and was 
retained in all models.  
 
Inclusion of MRI data from baseline to 3-years did not contribute additional information to the 
models, and baseline gadolinium enhancing lesions and new supatentorial lesions at 1 year 
remained the best predictors of PASAT and SDMT performance at 15 years.  
 
DISCUSSION 
We investigated early brain and spinal cord abnormalities over the first 3 years after a CIS to 
identify the most robust predictors of long-term outcomes after 15 years in people with relapse-
onset multiple sclerosis. The major, novel findings of this work include: (1) a consistent 
association of spinal cord lesions, both at the time of presentation and new spinal cord lesions 
over the first 3 years of follow-up, with development of secondary progressive multiple 
sclerosis and physical disability after 15 years; (2) a consistent association of asymptomatic 
gadolinium-enhancing lesions seen at the time of CIS with the development of secondary 
progressive multiple sclerosis and later physical and cognitive performance; and (3) a stronger 
association of MRI measures of focal inflammatory disease activity (i.e. lesions) with long-
term disease course, compared with brain and spinal cord atrophy, in the earliest stages of 
relapse-onset multiple sclerosis. 
 
Previous studies have suggested that lesions in clinically-eloquent sites, such as the brainstem, 
cerebellum and spinal cord, may be associated with short-term changes in EDSS in CIS patients 
(Minneboo et al., 2004; Swanton et al., 2009; Tintore et al., 2010; Brownlee et al., 2017; 
Arrambide et al., 2018). We evaluated the impact of lesion location on long-term disease 
outcomes in the most comprehensive analysis, considering not only global brain T2 lesion load 
but investigating separately the prognostic value of supatentorial, infratentorial and spinal cord 
lesions at the time of CIS, and early changes in lesion number at these sites. Spinal cord lesions 
seen at the time of CIS were associated with secondary progressive disease course and physical 
disability 15 years later. The importance of spinal cord lesions present at the time of CIS is 
emphasised in models incorporating changes in MRI measures over 1 and 3 years after CIS: 
baseline spinal cord lesions remained a significant predictor of EDSS at 15 years independent 
of changes in brain and spinal cord lesions and atrophy at 1 and 3 years. New spinal cord lesions 
over time were also associated with secondary progressive multiple sclerosis at 15 years and 
later physical disability. . Collectively these findings suggest that early spinal cord damage is 
an important mechanism underlying both development of physical disability and secondary 
progression in early relapse-onset multiple sclerosis.  
 
Pathological studies have found evidence of substantial axonal loss within chronic spinal cord 
lesions in multiple sclerosis (Lovas et al., 2000) and this may result in more widespread 
neuroaxonal loss at distant sites due to the effects of Wallerian degeneration (Dziedzic et al., 
2010). Neuroaxonal loss within spinal cord pathways involved in locomotion, sensation and 
sphincter function may have important functional consequences, ultimately resulting in 
physical disability. In a recent study that quantified cervical cord lesion load on axial images 
with high in-plane resolution, patients with secondary progressive multiple sclerosis had a 
higher spinal cord lesion load compared relapsing-remitting multiple sclerosis patients, even 
after adjusting for differences in disease duration (Kearney et al., 2015). These findings support 
the concept that focal spinal cord damage may be one of the factors involved in the 
development of secondary progression in relapse-onset multiple sclerosis. 
 
Current guidelines highlight the utility of spinal MRI in patients with suspected multiple 
sclerosis presenting with a spinal cord syndrome and those with non-specific brain lesions, or 
brain lesions not satisfying criteria for dissemination in space (Rovira et al., 2015). Spinal cord 
imaging is not done routinely because of the relatively modest additional diagnostic yield in 
unselected CIS patients (Arrambide et al., 2018). Our findings suggest that spinal cord MRI 
findings have significant prognostic value in CIS patients and may be useful in identifying 
those at high-risk of later disease progression and physical disability. The association of new 
spinal cord lesions over the first 3 years after a CIS over time, independent of brain MRI 
activity, might also suggest a role form spinal cord MRI when monitoring the course of 
multiple sclerosis. Incorporating spinal cord MRI into monitoring protocols is challenging not 
only because of increased cost and reduced resources associated with a longer scanning time, 
but also because of technical challenges that influence the sensitivity of lesion detection, 
including the MRI protocol used, pulsation artefacts from blood vessels and cerebrospinal 
fluid, and the experience of raters (Rovira et al., 2015; Wattjes et al., 2015). In this study spinal 
cord MRI was obtained on the same scanner with a standardised acquisition protocol, and all 
scans were reviewed by a single experienced Neuroradiologist, a situation that differs from 
routine clinical practice. 
Like the spinal cord, the brainstem and cerebellum contain pathways critical for balance and 
locomotion. Two previous studies found that infratentorial lesions seen at the time of 
presentation with CIS are associated with physical disability after 5-7 years, although neither 
study included spinal cord MRI (Minneboo et al., 2004; Tintore et al., 2010). Infratentorial 
lesions seen at the time of CIS were not independently associated with long-term outcomes, 
possibly because the effect is eclipsed by the impact of spinal cord lesions. New infratentorial 
lesions at 1 year were associated with long-term physical disability and secondary progression, 
but overall, we found a more consistent association of spinal cord rather than infratentorial 
lesions with long-term disease outcomes. 
 
Previous studies have found a relatively limited relationship between global brain T2 lesion 
load and long-term disease outcomes in relapse-onset multiple sclerosis (Fisniku et al., 2008; 
Optic Neuritis Study Group). In our study, supratentorial lesions at baseline were 
independently associated with EDSS and performance on tests of information processing speed 
after 15 years. Although supratentorial lesions showed a correlation with all long-term 
outcomes univariately (data not shown), their prognostic value was lost when other MRI 
measues were considered in the multivariable models. In contrast, asymptomatic gadolinium-
enhancing lesions (found in approximately one third of patients within 3 months of CIS) 
showed a consistent association with disease course at 15 years, physical disability (EDSS, 
walking speed, upper limb dexterity) and cognitive performance. Importantly, the association 
of baseline gadolinium-enhancing lesions remained even after including changes in MRI 
measures at 1 and 3 years in the statistical models. Gadolinium-enhancing lesions reflect areas 
of acute inflammatory activity associated with breakdown of the blood-brain barrier (Filippi et 
al., 2012), and potentially a greater severity of underlying inflammatory disease activity than 
T2 lesions.  
 
The association of early gadolinium-enhancing lesions with long-term disability is consistent 
with findings from natural history studies showing that the number of early relapses in the first 
few years after disease onset (a clinical measure of inflammatory disease activity) is associated 
with long-term disability and development of secondary progressive disease course in relapse-
onset multiple sclerosis (Scalfari et al., 2014). The “baseline” MRI scan in our study was done 
within 3 months after CIS onset (median 44 days). In many healthcare settings a diagnostic 
MRI scan would be done much sooner in patients presenting with acute optic neuritis or 
transverse myelitis. Our findings suggest that very early follow-up MRI in this group of patients 
done 6-12 weeks after CIS onset may provide valuable prognostic information, with 
asymptomatic gadolinium-enhancing lesions indicating a worse long-term prognosis, and 
supporting the early initiation of disease-modifying therapies.   
In this cohort of patients followed prospectively from CIS onset, lesional MRI measures, 
particularly lesion location (especially spinal cord) and lesion activity (i.e. gadolinium-
enhancement), were more consistently associated with long-term outcomes than early brain or 
spinal cord atrophy. A similar rate of whole brain atrophy was observed over the first 3 years 
after CIS onset in patients who developed multiple sclerosis irrespective of disease course at 
15 years. This is consistent with previous studies showing that whole brain atrophy begins early 
in the course of multiple sclerosis (Perez-Miralles et al., 2013), and progresses at a similar rate 
throughout the course of the disease, irrespective of disease phenotype or disease duration (De 
Stefano et al., 2010). Significant spinal cord atrophy was also observed over the first 3 years 
after CIS in this cohort, however, this was not independently associated with outcomes after 
15 years, at least when considered in conjunction with other MRI measures.   
 
A wide range of physical disability was observed at 15 years reflecting the variable prognosis 
of relapse-onset multiple sclerosis. In the patients with multiple sclerosis at 15 years physical 
disability was overall low: only 1 in 3 patients had an EDSS of ≥3 and only 1 in 5 developed 
secondary progressive multiple sclerosis. Although comprehensive neuropsychological testing 
wasn’t undertaken, most multiple sclerosis patients performed well on tests of information 
processing speed (even using a liberal cut-off value to define impairment) and less than half 
reported significant fatigue. Our findings contrast with the much worse prognosis reported in 
natural history studies done in the 1970s and 1980s (Confavreux et al., 2003; Scalfari et al., 
2014). There are a number of possible explanations. Firstly, we followed patients from the time 
of presentation with a CIS irrespective of disease status. The cohorts of patients followed up in 
natural history studies were enrolled at large hospital-based specialist multiple sclerosis clinics, 
potentially biased towards more severely affected patients. Secondly, patients with optic 
neuritis are the main subgroup in this cohort. Optic neuritis usually accounts for 30-40% of 
people with CIS (Tintore et al., 2015), compared with 80% in our cohort. Some studies have 
suggested that optic neuritis may be associated with a better prognosis compared with other 
CIS presentations, partly due to a lower rate of asymptomatic brain MRI abnormalities in optic 
neuritis patients (Tintore et al., 2005; Tintore et al., 2015). More than three quarters of the 
patients with optic neuritis in our cohort had an abnormal baseline MRI scan, indicating a group 
at high-risk for the development of multiple sclerosis and future physical disability (Fisniku et 
al., 2008; Tintore et al., 2015). Thirdly, during the course of the study disease-modifying 
therapies that reduce relapse rates and disease progression became available in the United 
Kingdom. However, less than a third of patients in the study received disease-modifying 
therapies, and most patients who were treated received first-line injectable therapies (beta 
interferon or glatiramer acetate). No adjustment was made for disease-modifying therapies in 
the multivariable models because criteria for treating patients in the United Kingdom at the 
time of the study required two clinically-significant attacks in two years in order to start 
treatment. More severely affected patients are likely to have received treatment leading to 
reverse causality in the prediction models. Finally, the diagnosis of multiple sclerosis was made 
using the McDonald criteria and includes people who in the past would have been labelled as 
having CIS rather than multiple sclerosis (Brownlee et al., 2015). The so-called Will-Rogers 
phenomenon describes the apparent improvement in prognosis with changes to diagnostic 
criteria over time (Sormani et al., 2008). Our findings of a more favourable long-term outcome 
than would be expected from natural history studies is consistent with other contemporary 
observational cohort studies (Kerbrat et al., 2015; Tintore et al., 2015; Cree et al., 2016) 
 
The strengths of this study include the prospective design, the uniquely long follow-up 
duration, the longitudinal MRI acquisition over the first 3 years after disease onset (including 
both brain and spinal cord MRI with gadolinium), and the very low number of patients lost to 
follow-up. In addition to examining EDSS, we also investigated early imaging predictors of 
secondary progressive multiple sclerosis and long-term cognitive performance important 
clinical outcomes that have not been investigated in previous in long-term, observational 
clinical-MRI studies. Our cohort were predominantly untreated over the first few years after 
disease onset providing insights into the natural history of relapse-onset multiple sclerosis in 
the MRI era. Some limitations also need to be noted. Firstly, an inherent limitation to all 
longitudinal observational studies is drop-out of subjects over time. Not all patients initially 
recruited into the study had follow-up MRI scans at 1 year and 3 years (~90% had at least one 
follow-up MRI). Secondly, clinical status after 15 years was assessed in a significant number 
of patients by telephone interview because not all patients were able to return for a follow-up 
visit to be examined in person. The use of telephone EDSS has been validated previously for 
use in clinical trials (Lechner-Scott et al., 2003) and has also been used in previous longitudinal 
clinical-MRI studies (Fisniku et al., 2008). Thirdly, although EDSS was assessed at disease 
onset, cognitive performance was only assessed cross-sectionally at 15-years. However, we 
estimated premorbid intelligence (measured using the NART) was considered in all models.  
Fourthly our aim was to examine the prognostic value of early MRI measures in patients with 
CIS and early multiple sclerosis. In models evaluating long-term outcomes we didn’t include 
the number of relapses or change in EDSS over the first 3 years after disease onset. Higher 
relapse number and progression of physical disability have already been established as markers 
of worse prognosis in natural history studies (Confavreux et al., 2003; Scalfari et al., 2014) , 
Fifthly, we estimated the rates of brain atrophy from 2-diemensional spin echo T1-weighted 
scans. While this acquisition can provide robust estimates of whole brain atrophy, we were 
unable to examine the prognostic impact of early tissue-specific brain atrophy. Recently, deep 
grey matter volume loss has been identified as a key mechanism responsible for  disease 
progression in multiple sclerosis (Eshaghi et al., 2018). We also did not acquire double-
inversion recovery or other advanced MRI sequences sensitive to the detection of focal grey 
matter lesions, which are known to be important in the disease progression in multiple sclerosis 
(Scalfari et al., 2018). Finally, although the mean duration of follow-up was over 15 years the 
course of multiple sclerosis often unfolds over much longer and the number of people 
developing secondary progression and worsening disability in this cohort is likely to increase 
with time.  However, the findings do identify early MRI predictors associated with a more 
aggressive course over the first 15 years after disease. 
 
CONCLUSION 
MRI abnormalities seen around the time of presentation with CIS and over the first few years 
after disease onset predict the development of long-term outcomes in relapse-onset multiple 
sclerosisS. Spinal cord and gadolinium-enhancing lesions showed a consistent association with 
the development of secondary progression and physical disability, and gadolinium-enhancing 
lesions with cognitive performance 15 years after disease onset. These findings suggest that 
the accrual of focal lesions in clinically-eloquent sites and the extent of early inflammatory 
disease activity are important predictors of long-term disability and secondary progression in 
relapse-onset multiple sclerosis. Conventional MRI measures available in routine clinical 
practice may be useful in counselling patients with CIS and early multiple sclerosis about long-
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Figure 1. Representative images of patients classified as clinically isolated syndrome 
  (CIS), relapsing-remitting multiple sclerosis (RRMS) and secondary  
  progressive multiple sclerosis (SPMS) at 15 years. MRI scans obtained at  
  baseline (the time of CIS), 1-year and 3-years. 
 
Figure 2.  EDSS scores after 15 years in the patients who developed multiple  
 sclerosis (n=119). 
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